Roche's Organ-Rejection Drug CellCept Increases Risk Of Birth Defects, Miscarriage, FDA Says

Main Category: Transplants / Organ Donations
Also Included In: Pregnancy / Obstetrics;  Women's Health / Gynecology;  Pediatrics / Children's Health
Article Date: 01 Nov 2007 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (3 votes)

Healthcare Prof:5 stars

5 (1 votes)


FDA on Monday said Roche's organ-rejection drug CellCept increases the risk of birth defects and miscarriage during the first trimester of pregnancy, Reuters reports. CellCept prevents organ rejection among kidney, liver and heart transplant recipients.

FDA issued a new black box warning to the drug's label about the increased risk of ear and facial deformities -- as well as problems in limbs, the heart and other organs -- among fetuses and infants exposed to the drug (Reuters, 10/29). FDA cited National Transplantation Pregnancy Registry data published in December 2006 of 24 women who were exposed to CellCept. The women had a total of 33 pregnancies, of which 15 resulted in a miscarriage and 18 in a live birth. Among the 18 live births, four infants had birth defects, according to Dow Jones. According to postmarketing data, which were collected by Roche and involved 77 women who took CellCept, there were 25 miscarriages and 14 defects among fetuses and infants. Six of the defects were ear abnormalities (Corbett Dooren, Dow Jones, 10/29).

In addition, FDA said the drug, which is known generically as mycophenolate mofetil, might lower blood levels of the hormones in oral contraceptives, making the pills less effective at preventing pregnancy. FDA said women of childbearing age should have a negative pregnancy test within one week before beginning treatment with CellCept, receive birth control counseling and use effective contraception (AP/Google.com, 10/29).

Roche sent a letter to physicians explaining the new warnings (Dow Jones, 10/29). According to FDA, prehuman trials of the drug found some signs of fetal defects (Reuters, 10/29).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on CellCept.


Article adapted by Medical News Today from original press release.
Visit our transplants / organ donations section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Kaiser. "Roche's Organ-Rejection Drug CellCept Increases Risk Of Birth Defects, Miscarriage, FDA Says." Medical News Today. MediLexicon, Intl., 1 Nov. 2007. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/87315.php>

APA
Kaiser. (2007, November 1). "Roche's Organ-Rejection Drug CellCept Increases Risk Of Birth Defects, Miscarriage, FDA Says." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/87315.php.

Please note: If no author information is provided, the source is cited instead.


Transplants / Organ Donations

Most Popular Articles



Follow Our Transplants News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Transplants / Organ Donations Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »